Category: FDA & Regulatory Policy (Page 2)

March 22, 2017

Statement on Congressional Action to Reauthorize the FDA’s Prescription Drug and Medical Device User Fee Programs

Alliance for Aging Research Vice President of Public Policy Cynthia Bens issued the following statement regarding congressional action taken this week to begin consideration of the U.S. Food and Drug Administration’s (FDA) prescription drug and medical device user fee programs.
March 7, 2017

FY 2018 Labor, HHS, Education, and Related Agencies Appropriations Testimony from the Alliance

This is testimony from the Alliance for Aging regarding the Fiscal Year 2018 Labor, Health and Human Services, Education, and Related Agencies appropriations process. It notes that "there is an ever-increasing need for sustained investment in the NIH, CDC, and AHRQ. Our testimony will highlight critical health concerns that disproportionately affect older adults and initiatives supported by our federal health agencies that are addressing them."  
February 27, 2017

Letter to President Trump on Federal Public Health and Biomedical Research Workforce and Federal Hiring

The Alliance for Aging Research joined other organizations in calling on President Donald J. Trump to consider of the vital role of the federal public health and biomedical research workforce to the United States as he considers long-term policy regarding federal hiring.
January 24, 2017

Comments on Oversight Framework for Molecular Diagnostic Tests, including Laboratory Developed Tests (LDTs)/Senate Version

This letter to Senate Majority Leader Sen. Mitch McConnell and Senate Minority Leader Sen. Charles Schumer that urges them to "make updating the oversight framework for all molecular diagnostic tests, including laboratory developed tests (LDTs), a priority early in the 115th Congress." 
January 24, 2017

Comments on Oversight Framework for Molecular Diagnostic Tests, including Laboratory Developed Tests (LDTs)/House Version

This letter to House Speaker Rep. Paul Ryan and House Minority Speaker Rep. Nancy Pelosi urges them to "make updating the oversight framework for all molecular diagnostic tests, including laboratory developed tests (LDTs), a priority early in the 115th Congress."
January 19, 2017

Alliance and 90+ Organizations Urge Senate Committee Chairs to Safeguard U.S. Vaccine Policy during Price Confirmation Process

The Alliance has joined with more than 90 national organizations in urging the Senate to ensure Secretary of HHS nominee Tom Price, M.D., is committed to protecting U.S. citizens from vaccine preventable diseases.
January 3, 2017

Alliance Issues Statement on the Protect Medical Innovation Act of 2017

The Alliance has issued the following statement from President and CEO Susan Peschin, MHS, regarding the introduction of the Protect Medical Innovation Act of 2017
December 15, 2016

AIM Coalition Held Second Annual Meeting

On December 2, the Aging in Motion (AIM) Coalition hosted its second annual meeting in Bethesda, Md., to discuss developments and advances in clinical research and treatment of sarcopenia.
December 7, 2016

Alliance Releases Statement on Passage of 21st Century Cures

The Senate today approved landmark legislation overhauling the development of medical treatments and cures for patients, which represents the culmination of a multi-year, bipartisan initiative in Congress. Here is a statement from Alliance President and CEO Sue Peschin.
December 2, 2016

AIM Coalition Meeting Spotlights Sarcopenia Research Advances

The Aging in Motion (AIM) Coalition hosted its second annual meeting with U.S. Food and Drug Administration (FDA) leaders and leading scientists, industry representatives, and advocates to discuss developments and advances in clinical research and treatment of sarcopenia in Bethesda, Md.